Treating canine Cushing's syndrome: Current options and future prospects

K. Sanders, H. S. Kooistra, S. Galac

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

Naturally occurring hypercortisolism, also known as Cushing's syndrome, is a common endocrine disorder in dogs that can be caused by an adenocorticotrophic hormone (ACTH)-producing pituitary adenoma (pituitary-dependent hypercortisolism, PDH; 80–85% of cases), or by an adrenocortical tumor (ACT; 15–20% of cases). To determine the optimal treatment strategy, differentiating between these two main causes is essential. Good treatment options are surgical removal of the causal tumor, i.e. hypophysectomy for PDH and adrenalectomy for an ACT, or radiotherapy in cases with PDH. Because these options are not without risks, not widely available and not suitable for every patient, pharmacotherapy is often used. In cases with PDH, the steroidogenesis inhibitor trilostane is most often used. In cases with an ACT, either trilostane or the adrenocorticolytic drug mitotane can be used. Although mostly effective, both treatments have disadvantages. This review discusses the current treatment options for canine hypercortisolism, and considers their mechanism of action, efficacy, adverse effects, and effect on survival. In addition, developments in both adrenal-targeting and pituitary-targeting drugs that have the potential to become future treatment options are discussed, as a more selective and preferably also tumor-targeted approach could have many advantages for both PDH and ACTs.
Originele taal-2Engels
Pagina's (van-tot)42-51
Aantal pagina's10
TijdschriftVeterinary Journal
Volume241
DOI's
StatusGepubliceerd - 1 nov. 2018
Extern gepubliceerdJa

Trefwoorden

  • Cushing's syndrome
  • Dog
  • Hypercortisolism
  • Pharmacotherapy
  • Treatment

Vingerafdruk

Duik in de onderzoeksthema's van 'Treating canine Cushing's syndrome: Current options and future prospects'. Samen vormen ze een unieke vingerafdruk.

Citeer dit